Homepage Featured News
Guardant Health Statement on Biden-Harris Administration’s Renewed Commitment to the Cancer Moonshot
Guardant Health stands with the Biden-Harris Administration’s renewed commitment to the Cancer Moonshot
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium
New Guardant Reveal™ data from interim analysis of COSMOS-CRC-01 demonstrates high performance for recurrence detection in early-stage colorectal cancer
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, a nearly 10,000-patient prospective, registrational study to evaluate the performance of its next-generation Guardant SHIELD blood test in detecting lung cancer in high-risk individuals ages 50-80.
Guardant Health to Participate Virtually in the 40th Annual J.P. Morgan Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference.
Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR™-2 Blood Test to Detect Colorectal Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has reached its target enrollment of 12,750 patients in ECLIPSE (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Encounter), a registrational study to evaluate the performance of its LUNAR™-2 blood test to detect colorectal cancer (CRC) in average-risk adults.
Guardant Health Presents Data Demonstrating Utility of Comprehensive Genetic Profiling with Guardant360® Liquid Biopsy Test to Guide Treatment for Advanced Breast Cancer Patients at 2021 San Antonio Breast Cancer Symposium
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present new data demonstrating the benefits of using the Guardant360® liquid biopsy test to help guide targeted therapy options for patients with advanced breast cancer at the 2021 San Antonio Breast Cancer Symposium (SABCS) on December 7-11.
Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer
The study, published in Nature Medicine, demonstrates that the Guardant360® test helps identify patients who may benefit from treatment and can identify alterations that predict resistance
Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom
Increased accessibility to Guardant Health’s liquid biopsy testing will enable clinicians to personalize treatments more accurately for patients with late-stage cancer
Data Presented at ACG Shows Guardant Health’s Blood-Based Test Accurately Detects Early-Stage Colorectal Cancer
This study indicates Guardant Health’s blood test could provide meaningful clinical performance in an average risk screening population
Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers
1,000-patient prospective study in 11 solid tumors will monitor ctDNA levels up to five years